南京独角兽IPO维立志博港交所敲钟，市值136亿港元

DoNews2025-07-25

DoNews7月25日消息，7月25日，南京维立志博生物科技股份有限公司（下称“维立志博”）正式登陆港交所。发行价为35港元/股，一度上涨127% 。截至目前，市值达到136亿港元。招股书显示，维立志博是一家处于临床阶段的生物科技公司，产品研究主要集中在治疗肿瘤、自身免疫性疾病及其他重大疾病。目前，公司在研管线有12项，其中有6款产品进入到临床阶段。具体来看，公司核心产品LBL-024已于2024...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2554957097?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-25 23:27","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2554957097","market":"hk","top_or_hot":-1,"title":"南京独角兽IPO维立志博港交所敲钟，市值136亿港元","media":"DoNews","content":"<div>\n<p>DoNews7月25日消息，7月25日，南京维立志博生物科技股份有限公司（下称“维立志博”）正式登陆港交所。发行价为35港元/股，一度上涨127% 。截至目前，市值达到136亿港元。招股书显示，维立志博是一家处于临床阶段的生物科技公司，产品研究主要集中在治疗肿瘤、自身免疫性疾病及其他重大疾病。目前，公司在研管线有12项，其中有6款产品进入到临床阶段。具体来看，公司核心产品LBL-024已于2024...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725234018971ead69&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>南京独角兽IPO维立志博港交所敲钟，市值136亿港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n南京独角兽IPO维立志博港交所敲钟，市值136亿港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-25 23:27 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725234018971ead69&s=b><strong>DoNews</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DoNews7月25日消息，7月25日，南京维立志博生物科技股份有限公司（下称“维立志博”）正式登陆港交所。发行价为35港元/股，一度上涨127% 。截至目前，市值达到136亿港元。招股书显示，维立志博是一家处于临床阶段的生物科技公司，产品研究主要集中在治疗肿瘤、自身免疫性疾病及其他重大疾病。目前，公司在研管线有12项，其中有6款产品进入到临床阶段。具体来看，公司核心产品LBL-024已于2024...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725234018971ead69&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0762540952.USD","symbol_name":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED INCOME \"AC\" (USD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725234018971ead69&s=b","article_id":"2554957097","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725234018971ead69&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2554957097","pubTimestamp":1753457270,"columns":[{"name":"港股","id":23,"label_key":"policyRegulatory"}],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"DoNews7月25日消息，7月25日，南京维立志博生物科技股份有限公司 正式登陆港交所。截至目前，市值达到136亿港元。招股书显示，维立志博是一家处于临床阶段的生物科技公司，产品研究主要集中在治疗肿瘤、自身免疫性疾病及其他重大疾病。财务数据显示，维立志博仅在2023年实现收入886.5万元。同期，公司研发开支分别为2.31亿元、1.86亿元、5775.1万元，高额的研发投入是亏损的主要原因之一。维立志博历经8轮融资，站满了投资机构。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"80388":"香港交易所-R","LU0762540952.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED INCOME \"AC\" (USD) ACC","LU0918141887.USD":"安联亚洲实际收益股票基金","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","LU0348816934.USD":"ALLIANZ TOTAL RETURN ASIAN EQUITY \"AT\" (USD)","LU1813983027.USD":"MANULIFE GF DRAGON GROWTH \"AA\" (USD) INC","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","LU1282649067.USD":"ALLIANZ ASIAN MULTI INCOME PLUS \"AMG\" (USD) INC A","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU0211977185.USD":"EASTSPRING INVESTMENTS GREATER CHINA EQUITY \"A\" ACC","SG9999001846.SGD":"Schroder Asian Equity Yield A Dis SGD","00388":"香港交易所","LU0577902298.EUR":"FULLERTON LUX FUNDS - ASIA GROWTH & INCOME EQUITIE \"I\" (EUR) ACC","LU0251144936.SGD":"Fidelity Sustainable Asia Equity A-SGD","LU0140636845.USD":"施罗德大中华区股票A Acc","BK1589":"北水核心资产","LU0048580855.USD":"富达大中华区A","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC","LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","SG9999002463.SGD":"LionGlobal China Growth SGD","LU1048588211.SGD":"Blackrock Asian Dragon A2 SGD-H","LU0886674414.USD":"CT (LUX) I ASIAN EQUITY INCOME \"AUP\" (USD) INC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU0577902371.SGD":"FULLERTON LUX FUNDS - ASIA GROWTH & INCOME EQUITIE \"I\" (SGD) ACC","LU0096374516.USD":"CT (LUX) I ASIA EQUITY INCOME \"DU\" (USD) ACC","LU0072462343.USD":"贝莱德亚洲巨龙基金","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0650527681.SGD":"Fidelity China Consumer A-SGD","LU0594300419.USD":"富达中国消费基金A","HKXCY":"香港交易所ADR","LU0797268264.HKD":"ALLIANZ TOTAL RETURN ASIAN EQUITY \"AT\" (HKD) ACC","LU1481107354.HKD":"HSBC GIF HONG KONG EQUITY \"AD\" (HKD) INC","LU0061477393.USD":"CT (LUX) I ASIA EQUITY INCOME \"AU\" (USD) ACC","SG9999001051.SGD":"United Asia Fund SGD","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","LU2257852520.SGD":"JPMorgan Funds - Asia Growth A (acc) SGD","LU0630378429.USD":"HSBC GIF ASIA PACIFIC EX JAPAN EQ HD \"AM2\" (USD) INC","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0384037296.USD":"ALLIANZ ASIAN MULTI INCOME PLUS \"AT\" (USD) ACC","LU0918141705.HKD":"ALLIANZ TOTAL RETURN ASIAN EQUITY \"AM\" (HKD) INC","LU0762542818.HKD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED INCOME \"AM\" (HKD) INC","LU0106959298.USD":"UBS (LUX) EQUITY FUND - EMERGING MARKETS SUSTAINABLE LEADERS (USD) \"P\" (USD) ACC"},"translate_title":"Nanjing Unicorn IPO Weili Zhibo Hong Kong Stock Exchange rings the bell, with a market value of HK $13.6 billion","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"80388":0.6,"HEXmain":0.6,"00388":0.9,"HKXCY":0.6},"content_text":"DoNews7月25日消息，7月25日，南京维立志博生物科技股份有限公司（下称“维立志博”）正式登陆港交所。发行价为35港元/股，一度上涨127% 。截至目前，市值达到136亿港元。招股书显示，维立志博是一家处于临床阶段的生物科技公司，产品研究主要集中在治疗肿瘤、自身免疫性疾病及其他重大疾病。目前，公司在研管线有12项，其中有6款产品进入到临床阶段。具体来看，公司核心产品LBL-024已于2024年进入针对晚期肺外神经内分泌癌的单臂注册临床试验，是全球达到注册临床试验阶段的首款4-1BB靶向候选药物。财务数据显示，维立志博仅在2023年实现收入886.5万元。2023年、2024年及2025年前三个月，公司净亏损分别为3.62亿元、3.01亿元和7536.7万元。同期，公司研发开支分别为2.31亿元、1.86亿元、5775.1万元，高额的研发投入是亏损的主要原因之一。维立志博历经8轮融资，站满了投资机构。此次IPO公司的基石投资者阵容同样豪华，包括正心谷资本、高毅资产、TruMed、OrbiMed、腾讯、易方达基金、Foresight Funds、Sage Partners、汉康资本，合计认购约5.42亿港元。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2554957097","isCrawlerRequest":true}